Gaudium IVF, Sillverton Industries among 7 IPOs approved by Sebi
India’s capital markets regulator Sebi has approved seven Initial Public Offerings. Companies in manufacturing, chemicals, logistics, healthcare, real estate, engineering, and precious metals can now raise funds. These approvals pave the way for significant investments and expansion plans across diverse industries. Investors can anticipate new opportunities as these firms prepare to go public.
Madhu Kela picks up stake in this stock market proxy player in Q3
Veteran investor Madhu Kela has bought a stake in Emkay Global. This signals new interest in the financial services firm. Ace investor Dolly Khanna has trimmed her holding. Emkay Global is a diversified financial services company. Kela’s entry is watched closely. Khanna’s move seems like portfolio rebalancing. The company’s shares rose on the news.
Pankaj Tibrewal on AI, capital markets and where investors should focus in 2026
Indian investors are focusing on midcap IT companies, private banks, and hard assets. Midcap IT firms are expected to grow faster due to AI adoption. Private banks are set for earnings growth after a period of consolidation. Hard assets like metals will benefit from supply constraints. These sectors offer opportunities for patient investors as the […]
Sandip Agarwal on IT sector: Improved margins, but growth expectations need a reset
Indian IT stocks saw a boost after a large-cap firm upgraded its FY26 revenue guidance. However, experts remain cautious, viewing the sector as mature with limited high-growth potential. While some see IT as a quasi-cash substitute for expensive sectors like FMCG, valuations are considered stretched.
Aritas Vinyl IPO: Check GMP, price band, subscription and other details
Aritas Vinyl’s Rs 38 crore IPO is now open, but the grey market shows no premium, suggesting a flat listing. The issue, priced between Rs 40-47, aims to fund working capital and a solar project. With a significant portion reserved for retail investors, the company manufactures artificial leather for various sectors and exports globally.
Angel One shares zoom over 7% after Q3 results, interim dividend, 1:10 stock split announcement
Angel One share price: On Friday, shares of Angel One soared as the company released its third-quarter earnings report, which highlighted a slight 4% year-over-year decline in net profit. Nevertheless, investor enthusiasm surged after the board announced an interim dividend of Rs 23 per share, coupled with an eye-catching 1:10 stock split.
Groww shares surge 4% on positive brokerage commentary post Q3 results. Should you buy, sell, or hold?
In a surprising twist, Billionbrains Garage Ventures’ stock surged on Friday despite a reported profit decline for Q3 of fiscal 2026. The notable increase in revenue, driven by market share expansion, impressed brokerages. Positive sentiments were echoed as Groww fortified its position in both stock and derivatives markets, with SIP inflows witnessing a remarkable uptick.
Oil flat as chances of US strike on Iran recedes
Oil prices remained steady on Friday. This came after fears of a U.S. strike on Iran eased. U.S. crude and gasoline inventories also rose. Venezuela has resumed oil exports. Analysts noted a swift unwinding of the ‘Iran premium’ from prices. Shell and OPEC provided outlooks on future energy demand and supply balances.
US stock leadership may broaden beyond tech
Investors are shifting focus from technology stocks to industrial, healthcare, and small-cap companies. This move signals a potential broadening of market leadership. Fourth-quarter earnings reports will be crucial in determining the sustainability of this trend. Experts believe conditions are favorable for this expansion, with AI benefits expected to reach various sectors.
Can domestic formulations shield Indian pharma from US pricing pressure in Q3?
Indian drugmakers anticipate a mixed third quarter. Domestic sales and new specialty drugs will drive growth. US generics will see new product boosts. Contract services and APIs are set for moderate gains. Sun Pharma and Lupin are poised for leadership. Cipla and Dr Reddy’s face softer US sales. Divi’s Laboratories expects strong custom synthesis growth.